-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics Announces Positive 18-Month Data from Phase 2b PARADIGM Study of PrimeC in ALS

Reuters·09/02/2025 12:36:32

Please log in to view news